Your browser doesn't support javascript.
loading
Generalization optimizing machine learning to improve CT scan radiomics and assess immune checkpoint inhibitors' response in non-small cell lung cancer: a multicenter cohort study.
Tonneau, Marion; Phan, Kim; Manem, Venkata S K; Low-Kam, Cecile; Dutil, Francis; Kazandjian, Suzanne; Vanderweyen, Davy; Panasci, Justin; Malo, Julie; Coulombe, François; Gagné, Andréanne; Elkrief, Arielle; Belkaïd, Wiam; Di Jorio, Lisa; Orain, Michele; Bouchard, Nicole; Muanza, Thierry; Rybicki, Frank J; Kafi, Kam; Huntsman, David; Joubert, Philippe; Chandelier, Florent; Routy, Bertrand.
Afiliação
  • Tonneau M; Department of Cancer Research, Centre de Recherche du Centre Hospitalier Universitaire de Montréal (CRCHUM), Montreal, QC, Canada.
  • Phan K; Université de Médecine, Lille, France.
  • Manem VSK; Imagia Canexia Health, Montreal, QC, Canada.
  • Low-Kam C; Institut Universitaire de Cardiologie et de Pneumologie de Quebec, Université Laval, Québec City, QC, Canada.
  • Dutil F; Department of Mathematics and Computer Science, University of Quebec at Trois-Rivières, Trois-Rivières, QC, Canada.
  • Kazandjian S; Imagia Canexia Health, Montreal, QC, Canada.
  • Vanderweyen D; Imagia Canexia Health, Montreal, QC, Canada.
  • Panasci J; Department of Medical Oncology, Jewish General Hospital, Montreal, QC, Canada.
  • Malo J; Department of Radiology, Centre Hospitalier de Sherbrooke (CHUS), Sherbrooke, QC, Canada.
  • Coulombe F; Department of Medical Oncology, Jewish General Hospital, Montreal, QC, Canada.
  • Gagné A; Department of Cancer Research, Centre de Recherche du Centre Hospitalier Universitaire de Montréal (CRCHUM), Montreal, QC, Canada.
  • Elkrief A; Institut Universitaire de Cardiologie et de Pneumologie de Quebec, Université Laval, Québec City, QC, Canada.
  • Belkaïd W; Institut Universitaire de Cardiologie et de Pneumologie de Quebec, Université Laval, Québec City, QC, Canada.
  • Di Jorio L; Department of Cancer Research, Centre de Recherche du Centre Hospitalier Universitaire de Montréal (CRCHUM), Montreal, QC, Canada.
  • Orain M; Hemato-Oncology Division, Centre Hospitalier de l'université de Montreal, Montreal, QC, Canada.
  • Bouchard N; Department of Cancer Research, Centre de Recherche du Centre Hospitalier Universitaire de Montréal (CRCHUM), Montreal, QC, Canada.
  • Muanza T; Imagia Canexia Health, Montreal, QC, Canada.
  • Rybicki FJ; Institut Universitaire de Cardiologie et de Pneumologie de Quebec, Université Laval, Québec City, QC, Canada.
  • Kafi K; Department of Oncology, Centre Hospitalier de Sherbrooke (CHUS), Sherbrooke, QC, Canada.
  • Huntsman D; Department of Medical Oncology, Jewish General Hospital, Montreal, QC, Canada.
  • Joubert P; Department of Radiation Oncology, Lady Davis Institute of the Jewish General Hospital, Montreal, QC, Canada.
  • Chandelier F; Imagia Canexia Health, Montreal, QC, Canada.
  • Routy B; Imagia Canexia Health, Montreal, QC, Canada.
Front Oncol ; 13: 1196414, 2023.
Article em En | MEDLINE | ID: mdl-37546399
Background: Recent developments in artificial intelligence suggest that radiomics may represent a promising non-invasive biomarker to predict response to immune checkpoint inhibitors (ICIs). Nevertheless, validation of radiomics algorithms in independent cohorts remains a challenge due to variations in image acquisition and reconstruction. Using radiomics, we investigated the importance of scan normalization as part of a broader machine learning framework to enable model external generalizability to predict ICI response in non-small cell lung cancer (NSCLC) patients across different centers. Methods: Radiomics features were extracted and compared from 642 advanced NSCLC patients on pre-ICI scans using established open-source PyRadiomics and a proprietary DeepRadiomics deep learning technology. The population was separated into two groups: a discovery cohort of 512 NSCLC patients from three academic centers and a validation cohort that included 130 NSCLC patients from a fourth center. We harmonized images to account for variations in reconstruction kernel, slice thicknesses, and device manufacturers. Multivariable models, evaluated using cross-validation, were used to estimate the predictive value of clinical variables, PD-L1 expression, and PyRadiomics or DeepRadiomics for progression-free survival at 6 months (PFS-6). Results: The best prognostic factor for PFS-6, excluding radiomics features, was obtained with the combination of Clinical + PD-L1 expression (AUC = 0.66 in the discovery and 0.62 in the validation cohort). Without image harmonization, combining Clinical + PyRadiomics or DeepRadiomics delivered an AUC = 0.69 and 0.69, respectively, in the discovery cohort, but dropped to 0.57 and 0.52, in the validation cohort. This lack of generalizability was consistent with observations in principal component analysis clustered by CT scan parameters. Subsequently, image harmonization eliminated these clusters. The combination of Clinical + DeepRadiomics reached an AUC = 0.67 and 0.63 in the discovery and validation cohort, respectively. Conversely, the combination of Clinical + PyRadiomics failed generalizability validations, with AUC = 0.66 and 0.59. Conclusion: We demonstrated that a risk prediction model combining Clinical + DeepRadiomics was generalizable following CT scan harmonization and machine learning generalization methods. These results had similar performances to routine oncology practice using Clinical + PD-L1. This study supports the strong potential of radiomics as a future non-invasive strategy to predict ICI response in advanced NSCLC.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Front Oncol Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Front Oncol Ano de publicação: 2023 Tipo de documento: Article